Evidence sharply contradicts PhRMA’s contention that its member companies need unregulated drug prices to generate profits that they then reinvest in drug innovation. This is a long read that goes on to question the practice […]
Stock buybacks come at the cost of technological innovation William Lazonick, professor emeritus of economics at University of Massachusetts Matt Hopkins, PhD candidate at SOAS University of London Cross-posted from the website of the Institute […]
Ever heard that a corporation’s sole duty is to maximize value for shareholders? In the go-go ‘80s, business schools, government organizations, and most public companies took up this mantra. It stuck around. William Lazonick, emeritus […]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes
